New inspection service for labels

To simplify label material testing in the pharmaceutical industry, Avery Dennison is launching the new AD Procerta laboratory and testing service.

The creation of labels in the pharmaceutical sector is complex. To simplify the process, Avery Dennison is introducing a new laboratory and testing service. AD Procerta is set to transform labelling material testing in the pharmaceutical industry. 

When creating labels for pharmaceutical products, such as medicines, there are many different ways of labelling. Variables that must be perfectly executed and installed for patient safety. You need to understand the numerous legal and regulatory requirements and how the labels will perform in certain environments to ensure the labels are robust enough to meet the end user's requirements. Pharmaceutical packaging engineers and brand owners now have access to a service that can simplify and streamline this process.

„We have identified a market need. This is a Market need that is not really being met at the moment. There are some excellent third-party labs, but either they lack the expertise specifically for self-adhesive labels or they have extremely long lead times.“

Benoît Jourde, Senior Manager New Growth Platforms Europe at Avery Dennison

Display

Squares in silver and purple.
The function of the materials is tested in the AD Procerta laboratory. (Image: Avery Dennison)

Leiden Bio Science Park in the Netherlands is home to the laboratory of AD Procerta, that provides access to a wide range of testing options offers.

„At the centre, under the guidance of a team of experts, a large number of label-specific tests to determine whether a labelling material is suitable for a particular application.“

Jos van Noort, Principal Scientist Global Pharma Innovations at Avery Dennison

Several large pharmaceutical companies have been trialling the service in a pilot project over the past two years, with the aim of rolling it out this year. „Having learnt from these pilot customers, we are now working with more than 5 large pharmaceutical companies and some smaller ones,“ concludes Benoit.

Source: Avery Dennison

More messages about labels